GPR120 Rabbit anti-Human, Polyclonal, Bioss
Manufacturer: Bioss
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 50-198-8671-Each-of-1 | In Stock | ₹ 38,381.25 |
50-198-8671 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 38,381.25
GST (18%): ₹ 6,908.625
Total Price: ₹ 45,289.875
Antigen
GPR120
Classification
Polyclonal
Conjugate
Unconjugated
Gene
FFAR4
Gene Alias
AI552415; BMIQ10; FFAR4; Free fatty acid receptor 4; G protein-coupled receptor 120; GPCR120; Gpr120; GPR129; G-protein coupled receptor 120; G-protein coupled receptor 129; G-protein coupled receptor GT01; G-protein coupled receptor PGR4; G-protein-coupled receptor GT01; GT01; KPG_013; O3far1; Omega-3 fatty acid receptor 1; PGR4
Host Species
Rabbit
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
338557
Content And Storage
-20°C
Form
Liquid
Applications
Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot
Concentration
1 μg/mL
Formulation
PBS with 1% BSA, 50% glycerol and 0.09% sodium azide; pH
Gene Accession No.
Q5NUL3
Gene Symbols
FFAR4
Immunogen
KLH conjugated synthetic peptide derived from human G protein coupled receptor 120.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- An EST for GPR120 has been isolated from a human colon cancer library
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This ''turn-off'' activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.